CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Blueprint Medicines Corporation - BPMC CFD

86.99
2.11%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.52
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Blueprint Medicines Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 88.82
Open* 88.19
1-Year Change* 80.35%
Day's Range* 85.85 - 89.42
52 wk Range 37.82-94.00
Average Volume (10 days) 739.02K
Average Volume (3 months) 18.26M
Market Cap 4.84B
P/E Ratio -100.00K
Shares Outstanding 60.79M
Revenue 216.20M
EPS -9.20
Dividend (Yield %) N/A
Beta 0.63
Next Earnings Date Feb 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 18, 2024 88.82 2.15 2.48% 86.67 91.45 85.89
Apr 17, 2024 88.26 3.30 3.88% 84.96 89.43 84.56
Apr 16, 2024 85.39 1.37 1.63% 84.02 87.85 83.82
Apr 15, 2024 84.53 -1.20 -1.40% 85.73 87.61 84.05
Apr 12, 2024 86.78 -5.15 -5.60% 91.93 92.53 86.69
Apr 11, 2024 92.12 1.98 2.20% 90.14 92.49 89.95
Apr 10, 2024 89.88 3.92 4.56% 85.96 90.41 81.99
Apr 9, 2024 92.06 0.21 0.23% 91.85 93.69 90.15
Apr 8, 2024 91.47 2.23 2.50% 89.24 92.33 89.24
Apr 5, 2024 91.45 2.66 3.00% 88.79 91.54 87.52
Apr 4, 2024 90.59 0.14 0.15% 90.45 92.84 90.21
Apr 3, 2024 88.07 -1.65 -1.84% 89.72 93.17 88.07
Apr 2, 2024 91.41 -1.65 -1.77% 93.06 93.61 89.98
Apr 1, 2024 96.33 3.71 4.01% 92.62 96.93 92.62
Mar 28, 2024 94.67 0.29 0.31% 94.38 95.66 90.71
Mar 27, 2024 94.19 5.14 5.77% 89.05 94.75 88.71
Mar 26, 2024 89.50 1.36 1.54% 88.14 92.08 87.94
Mar 25, 2024 88.02 1.09 1.25% 86.93 89.38 86.83
Mar 22, 2024 86.92 -3.36 -3.72% 90.28 90.28 86.69
Mar 21, 2024 89.78 1.59 1.80% 88.19 91.26 88.19

Blueprint Medicines Corporation Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

14:00

Country

US

Event

Blueprint Medicines Corp To Discuss Emerging Opportunities for Mast Cell-Targeted Therapeutics Call
Blueprint Medicines Corp To Discuss Emerging Opportunities for Mast Cell-Targeted Therapeutics Call

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Blueprint Medicines Corp Earnings Release
Q1 2024 Blueprint Medicines Corp Earnings Release

Forecast

-

Previous

-
Thursday, June 20, 2024

Time (UTC)

19:30

Country

US

Event

Blueprint Medicines Corp Annual Shareholders Meeting
Blueprint Medicines Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, July 31, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Blueprint Medicines Corp Earnings Release
Q2 2024 Blueprint Medicines Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 204.036 180.08 793.735 66.512 44.521
Revenue 204.036 180.08 793.735 66.512 44.521
Total Operating Expense 741.554 822.061 485.028 427.838 291.549
Selling/General/Admin. Expenses, Total 237.374 195.293 157.743 96.388 47.928
Research & Development 477.419 601.033 326.86 331.45 243.621
Operating Income -537.518 -641.981 308.707 -361.326 -247.028
Interest Income (Expense), Net Non-Operating -16.767 2.386 6.599 13.732 -0.073
Other, Net 2.004 -1.489 -0.366 -0.1 10.459
Net Income Before Taxes -552.281 -641.084 314.94 -347.694 -236.642
Net Income After Taxes -557.517 -644.085 313.882 -347.694 -236.642
Net Income Before Extra. Items -557.517 -644.085 313.882 -347.694 -236.642
Net Income -557.517 -644.085 313.882 -347.694 -236.642
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -557.517 -644.085 313.882 -347.694 -236.642
Income Available to Common Incl. Extra. Items -557.517 -644.085 313.882 -347.694 -236.642
Diluted Net Income -557.517 -644.085 313.882 -347.694 -236.642
Diluted Weighted Average Shares 59.642 58.518 56.168 47.829 43.867
Diluted EPS Excluding Extraordinary Items -9.34772 -11.0066 5.58827 -7.26952 -5.39453
Diluted Normalized EPS -9.34772 -11.0066 5.58827 -7.26952 -5.39453
Cost of Revenue, Total 17.813 17.934 0.425
Gross Profit 186.223 162.146 793.31
Other Operating Expenses, Total 8.948 7.801
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 56.566 57.57 63.287 38.781 65.977
Revenue 56.566 57.57 63.287 38.781 65.977
Cost of Revenue, Total 2.782 2.323 3.175 4.848 3
Gross Profit 53.784 55.247 60.112 33.933 62.977
Total Operating Expense 185.546 185.551 187.494 188.58 190.254
Selling/General/Admin. Expenses, Total 70.741 71.931 70.95 64.02 57.608
Research & Development 110.252 110.063 112.073 117.84 127.981
Operating Income -128.98 -127.981 -124.207 -149.799 -124.277
Interest Income (Expense), Net Non-Operating -3.808 -3.996 -5.819 -9.24 -8.396
Other, Net -0.728 -0.626 0.986 1.429 0.396
Net Income Before Taxes -133.516 -132.603 -129.04 -157.61 -132.277
Net Income After Taxes -133.713 -132.793 -129.56 -158.646 -133.163
Net Income Before Extra. Items -133.713 -132.793 -129.56 -158.646 -133.163
Net Income -133.713 -132.793 -129.56 -158.646 -133.163
Income Available to Common Excl. Extra. Items -133.713 -132.793 -129.56 -158.646 -133.163
Income Available to Common Incl. Extra. Items -133.713 -132.793 -129.56 -158.646 -133.163
Diluted Net Income -133.713 -132.793 -129.56 -158.646 -133.163
Diluted Weighted Average Shares 60.688 60.516 60.126 59.876 59.758
Diluted EPS Excluding Extraordinary Items -2.20329 -2.19435 -2.15481 -2.64958 -2.22837
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.20329 -2.19435 -2.15481 -2.64958 -2.22837
Other Operating Expenses, Total 1.771 1.234 1.296 1.872 1.665
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1046.65 554.025 927.759 516.786 499.787
Cash and Short Term Investments 944.992 477.114 871.849 483.554 494.012
Cash & Equivalents 119.709 209.948 684.636 113.938 68.064
Short Term Investments 825.283 267.166 187.213 369.616 425.948
Total Receivables, Net 36.938 37.03 25.309 23.412 0.215
Accounts Receivable - Trade, Net 36.938 37.03 25.309 23.412 0.215
Prepaid Expenses 35.024 18.064 22.02 9.82 5.56
Total Assets 1349.9 1252.22 1718.39 707.694 540.124
Property/Plant/Equipment, Total - Net 115.198 120.862 101.668 111.114 29.627
Property/Plant/Equipment, Total - Gross 146.48 146.28 121.399 124.798 38.282
Accumulated Depreciation, Total -31.282 -25.418 -19.731 -13.684 -8.655
Long Term Investments 133.48 557.529 677.873 64.406 0
Other Long Term Assets, Total 54.573 19.809 11.093 15.388 10.71
Total Current Liabilities 183.234 149.765 130.802 106.482 60.323
Accounts Payable 2.729 8.333 4.37 4.793 3.298
Accrued Expenses 141.702 129.922 113.873 95.529 51.711
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 16.851
Other Current Liabilities, Total 21.952 11.51 12.559 6.16 5.314
Total Liabilities 835.225 281.49 248.305 243.335 121.115
Total Long Term Debt 122.232 0 0 0 0
Long Term Debt 122.232
Other Liabilities, Total 529.759 131.725 117.503 136.853 60.792
Total Equity 514.677 970.735 1470.09 464.359 419.009
Common Stock 0.06 0.059 0.058 0.049 0.044
Additional Paid-In Capital 2358.02 2250.25 2106.6 1412.08 1016.69
Retained Earnings (Accumulated Deficit) -1832.96 -1275.44 -631.356 -945.238 -597.545
Other Equity, Total -10.443 -4.133 -5.214 -2.535 -0.18
Total Liabilities & Shareholders’ Equity 1349.9 1252.22 1718.39 707.694 540.124
Total Common Shares Outstanding 59.9589 59.1411 57.7935 49.2722 44.037
Preferred Stock - Non Redeemable, Net 0 0 0
Total Inventory 29.697 21.817 8.581
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 808.172 811.335 900.344 1046.65 1227.67
Cash and Short Term Investments 712.984 722.634 822.161 944.992 1136.96
Cash & Equivalents 55.972 75.527 169.724 119.709 291.43
Short Term Investments 657.012 647.107 652.437 825.283 845.535
Total Receivables, Net 41.254 38.267 31.303 36.938 21.915
Accounts Receivable - Trade, Net 41.254 38.267 31.303 36.938 21.915
Total Inventory 16.457 17.016 17.521 29.697 35.253
Prepaid Expenses 37.477 33.418 29.359 35.024 33.532
Total Assets 1105.3 1106.44 1220.37 1349.9 1458.39
Property/Plant/Equipment, Total - Net 115.84 114.486 113.409 115.198 117.371
Property/Plant/Equipment, Total - Gross 146.48
Accumulated Depreciation, Total -31.282
Long Term Investments 114.242 113.932 139.15 133.48 55.675
Other Long Term Assets, Total 67.045 66.692 67.467 54.573 57.681
Total Current Liabilities 197.384 169.028 172.684 183.234 175.51
Accounts Payable 6.963 6.979 10.563 2.729 4.233
Accrued Expenses 122.053 112.454 119.622 141.702 130.879
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 38.147 31.738 25.117 21.952 25.108
Total Liabilities 902.688 795.315 806.072 835.225 818.085
Total Long Term Debt 208.157 122.146 122.13 122.232 123.06
Other Liabilities, Total 497.147 504.141 511.258 529.759 519.515
Total Equity 202.611 311.13 414.298 514.677 640.307
Common Stock 0.061 0.061 0.06 0.06 0.06
Additional Paid-In Capital 2434.26 2410.6 2381.36 2358.02 2329.39
Retained Earnings (Accumulated Deficit) -2229.02 -2095.31 -1962.52 -1832.96 -1674.31
Other Equity, Total -2.683 -4.221 -4.602 -10.443 -14.826
Total Liabilities & Shareholders’ Equity 1105.3 1106.44 1220.37 1349.9 1458.39
Total Common Shares Outstanding 60.7407 60.6383 60.4163 59.9589 59.8085
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 30.221 17.857 17.382 16.851 15.29
Long Term Debt 208.157 122.146 122.13 122.232 123.06
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -557.517 -644.085 313.882 -347.694 -236.642
Cash From Operating Activities -502.277 -298.653 387.035 -278.015 -175.009
Cash From Operating Activities 11.735 6.479 6.559 5.259 4.246
Non-Cash Items 97.274 362.633 82.212 54.695 26.147
Cash Interest Paid 9.814 0 0.005 0.267
Changes in Working Capital -53.769 -23.68 -15.618 9.725 31.24
Cash From Investing Activities -149.541 -225.86 -434.249 -16.466 -161.088
Capital Expenditures -8.919 -3.089 -3.159 -14.013 -12.677
Other Investing Cash Flow Items, Total -140.622 -222.771 -431.09 -2.453 -148.411
Cash From Financing Activities 561.81 50.716 617.759 340.638 4.454
Financing Cash Flow Items 415.828 0 0 -0.4 -0.281
Issuance (Retirement) of Stock, Net 8.196 50.716 617.759 341.038 6.425
Issuance (Retirement) of Debt, Net 137.786 0 0 -1.69
Net Change in Cash -90.215 -474.685 570.2 46.175 -331.643
Cash Taxes Paid 6.505 0.694 0.778 0.185
Foreign Exchange Effects -0.207 -0.888 -0.345 0.018
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -129.56 -557.517 -398.871 -265.709 -105.999
Cash From Operating Activities -122.961 -502.277 -380.872 -250.982 -132.726
Cash From Operating Activities 3.684 11.735 4.719 3.098 1.628
Non-Cash Items 29.336 97.274 60.743 53.403 26.249
Cash Taxes Paid 0.311 6.505 4.018 0.771 0.169
Changes in Working Capital -26.421 -53.769 -47.463 -41.774 -54.604
Cash From Investing Activities 172.791 -149.541 -96.258 35.977 -41.09
Capital Expenditures -2.584 -8.919 -7.438 -3.709 -1.153
Other Investing Cash Flow Items, Total 175.375 -140.622 -88.82 39.686 -39.937
Cash From Financing Activities 0 561.81 559.319 178.762 1.264
Issuance (Retirement) of Stock, Net 0 8.196 5.686 3.762 1.264
Foreign Exchange Effects 0.197 -0.207 -0.685 -0.306 -0.197
Net Change in Cash 50.027 -90.215 81.504 -36.549 -172.749
Financing Cash Flow Items 415.828 415.836 175
Cash Interest Paid 7.084 9.814 2.956
Issuance (Retirement) of Debt, Net 137.786 137.797

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Blueprint Medicines Corporation Company profile

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).

Industry: Biotechnology & Medical Research (NEC)

45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

XRP/USD

0.51 Price
-0.460% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,391.98 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.40

ETH/USD

3,091.51 Price
+0.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

64,589.75 Price
+1.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading